This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange added 1.25 points to 681.32 Wednesday. One of the TSX-V's busiest shell-makers, Ron Schmeichel, has filed a preliminary prospectus to list his 18th capital pool shell, Mira VII Acquisition Corp. (He has been president or chief executive officer of 18 capital pool shells, and helped package deals for more than 20 shells). Richardson GMP Ltd. will handle Mira VII's $250,000 initial public offering of 2.5 million shares at 10 cents.

Mira VII has 10 million shares in escrow that sold at five cents to the shell's three directors, Mr. Schmeichel, Jordan Kupinsky and Kevin Taylor. President Schmeichel, 47, is the largest shareholder with four million escrow shares. He is a lawyer and a co-founder of the JJR Private Capital Inc. shell-manufacturing facility in Toronto. We will discuss his record in the shell sector momentarily. Mr. Kupinsky, a lawyer with three million escrow shares, is president of JJR Private Capital. Mr. Taylor, also with three million escrow shares, lives in Fort Lauderdale, where he manages a telecom and renewable energy fund focused on investments in the Caribbean. The Mira VII trio has packaged several high-profile deals together over the past few years, including Concordia Healthcare Corp. (CXR: $84.99), a profitable pharmaceutical company that was one of the best-performing stocks on the TSX in 2014, and has had an equally pleasing start to 2015. Mr. Schmeichel has been the chairman of Concordia since it went public on Christmas Eve in 2013, opening at $6.26. Mr. Kupinsky is a Concordia director. Mr. Taylor was the second-largest shareholder with 3,072,500 shares when Concordia listed, though last June he sold one million of his shares at $30 each; according to SEDI, he still owns 2,072,500 shares, now worth $176-million. The stock has climbed to $84.99 from $6.26 in 15 months and the company recently reported a deal to acquire assets from a Swiss company, Covis Pharma Holdings Sarl, for $1.2-billion (U.S.) in cash.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS